ESR1 and breast cancer: The phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) (PAM) pathway is frequently activated in breast cancer, with PIK3CA being the most commonly mutated gene of significance in estrogen receptor (ER) positive breast cancer.1